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Abstract
Background: Raloxifene, a selective estrogen receptor modulator, exhibits quite large and unexplained
interindividual variability in pharmacokinetics and pharmacodynamics. The aim of this study was to determine the
role of organic-anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants in the
pharmacokinetics and pharmacodynamics of raloxifene.
Methods: To test the role of OATP1B1 and OATP1B3 transporters on hepatic uptake of raloxifene and its
metabolites an in vitro model of Chinese Hamster Ovary cells expressing OATP1B1 or OATP1B3 was employed. The
influence of OATP1B1 and OATP1B3 genetic variants on in vivo pharmacokinetics and pharmacodynamics was
evaluated in 53 osteoporotic postmenopausal women treated with raloxifene.
Results: Our in vitro results showed that raloxifene and two of the three metabolites, raloxifene-4'-β-glucuronide
(M2) and raloxifene-6,4'-diglucuronide (M3), interact with OATP1B1 and OATP1B3. Higher M3 and total raloxifene
serum concentrations in patients correlated with lower serum levels of bone resorption marker, serum C-terminal
telopeptide fragments of type I collagen, indicating a higher antiresorptive effect of raloxifene. Higher
concentrations of M2 correlated with higher increase of lumbar spine bone mineral density supporting the
raloxifene vertebral fracture specific protection effect. Finally, raloxifene, M3 and total raloxifene serum
concentrations were significantly higher in patients with SLCO1B1 c.388A>G polymorphism and *1b haplotype
implicating a considerable genetic effect on pharmacokinetics and pharmacodynamics of raloxifene.
Conclusions: These findings indicate that SLCO1B1 c.388A>G polymorphism could play an important role in
pharmacokinetics and pharmacodynamics of raloxifene.
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Background
Raloxifene is a selective estrogen receptor modulator which
is approved worldwide for the prevention and treatment of
postmenopausal osteoporosis and for the prevention of
breast cancer in postmenopausal women. Raloxifene treat-
ment reduces the risk for vertebral fractures [1], increases
bone mineral density of lumbar spine (BMD-LS) and of
femoral neck (BMD-FN) [2], decreases serum concentra-
tions of bone turnover markers [3,4], stabilizes quantitative
ultrasound parameters (QUS) [5,6] and also reduces the risk
of invasive breast cancer in postmenopausal women [7]. Be-
side its beneficial effects on bone and breast tissue, raloxifene
decreases total cholesterol, LDL-cholesterol, fibrinogen, lipo-
protein(a), high-sensitivity C-reactive protein, homocysteine
and cell adhesion molecules levels [8-12]. In postmenopausal
women, the favourable effects on cardiovascular risk factors
do not seem to translate overall into cardio-protection [13]
except in those less than 60 years of age, where a lower inci-
dence of coronary events is observed [14].
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Raloxifene is subjected to an extensive first-pass metabol-
ism: 60% of the peroral dose is absorbed but only 2% of un-
changed drug reaches the systemic circulation [15]. First-
pass metabolism occurs mainly due to conjugation by
UDP-glucuronosyltransferases to raloxifene glucuro-
nides, raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-
glucuronide (M2) [16] and to raloxifene-6,4'-diglucuro-
nide (M3) [17]. The glucuronides show very little affinity
for the estrogen receptors. However, these metabolites
can be readily reconverted to active raloxifene in various
organs and hence contribute significantly to raloxifene
action [18]. Raloxifene, especially in the form of glucur-
onides, is excreted into bile and completes the entero-
hepatic cycle and this prolongs its biological half-life to
28 h [15]. Raloxifene is subject to large inter- and intra-
individual variability of its clearance and volume of dis-
tribution [17] and its pharmacokinetics are still not
completely understood, especially the role of transport
systems mediating cellular uptake of raloxifene and its
metabolites remain to be elucidated. Organic anion-
transporting polypeptides (OATP) appear to be particu-
larly important in the disposition of many drugs in clin-
ical use today. Specifically, the liver-enriched OATP1B
subfamily members OATP1B1 and OATP1B3 located at
the basolateral membrane of hepatocytes exhibit a broad
substrate specificity and the ability to transport different
drugs [19]. A number of single nucleotide polymorphisms
(SNPs) have been found within SLCO1B1 and/or SLCO1B3
genes encoding OATP1B1 and OATP1B3 proteins, respect-
ively and were shown to influence the pharmacokinetics
and/or pharmacodynamics of many drugs [20-25]. As liver
is the main organ governing systemic clearance of raloxi-
fene, the aim of the present study was to identify the role of
OATP1B1 and OATP1B3 transporters in hepatic uptake of
raloxifene species and to investigate the influence of
SLCO1B1 and SLCO1B3 genetic polymorphisms on
pharmacokinetics and pharmacodynamics of raloxifene in
women with postmenopausal osteoporosis.
Materials and methods
Chemicals
Radiolabeled [3H] estrone-3-sulfate (E-3-S) was obtained
from PerkinElmer Life Sciences (Boston, MA). Cell culture
reagents, beta-glucuronidase from Helix pomatia, E-3-S,
raloxifene hydrochloride and haloperidol were from
Sigma Aldrich Chemie (Deisenhofen, Germany). Chin-
ese Hamster Ovary (CHO) cells stably transfected with
SLCO1B1 or SLCO1B3 are described in Treiber et al.
[26] and Gui et al. [27]. Raloxifene metabolites M1, M2
and M3 were synthesised by incubating raloxifene
hydrochloride with Streptomyces sp. ATCC 55043 [28]
followed by chromatographic purification and lyophil-
isation. Purity and identification were checked by high
performance liquid chromatography (HPLC) and liquid
chromatography tandem mass spectrometry (LC-MS/
MS). Stock solutions of raloxifene, M1, M2 and M3 were
prepared in dimethyl sulfoxide (DMSO).
Transport experiments in CHO cells
CHO cells were grown at 37°C in a humidified 5% CO2 at-
mosphere in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% FBS, 50 μg/mL L-proline,
100 U/mL penicillin and 100 μg/mL streptomycin. For
OATP1B1 or OATP1B3 expressing CHO cells the
medium was supplemented with geneticin (100 μg/mL).
For transport assays, cells were split from a confluent
flask at 40,000 cells per dish on 3 cm dishes from Corn-
ing (NY, USA) and 48 h later the medium was replaced
with a medium containing 5 mM sodium-butyrate to in-
duce nonspecific gene expression [29]. After another
24 h, the cells were 80 to 90% confluent, and transport
experiments were preformed as described in Leuthold
et al. [30]. Briefly, cells were rinsed three times with pre-
warmed (37°C) uptake buffer (116.4 mM NaCl, 5.3 mM
KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose
and 20 mM Hepes/Tris pH 7.4). The transport experiment
was started by adding 1 mL of uptake buffer containing
0.3 μCi/mL of [3H]E-3-S in 0.5 μM E-3-S in the absence or
presence of inhibitors: raloxifene (10 μM), M1 (10 μM), M2
(10 μM), M3 (4 μM) and indocyanine green (ICG, 5 μM) as
a positive control for inhibition [31]. After 0 and 5 min, the
uptake solution was aspirated, the cells rinsed four times
with 2 mL of ice-cold uptake buffer and solubilised with
1 mL of 1% Triton X-100. Aliquots were used for liquid
scintillation counting and determination of protein concen-
tration. Uptake was calculated by first subtracting the 0 min
time point and second correcting the uptake of the CHO-
expressing cells by the uptake obtained in CHO wild type
cells. Each experiment was performed on four parallels.
Study participants
A total of 57 Caucasian postmenopausal female patients
with osteoporosis were enrolled in the study. The
patients were selected according to the following inclu-
sion criteria: >5 years of menopause, aged <70 years, pres-
ence of osteoporosis, defined as low BMD (T score<−2.5
SD) or radiographically apparent vertebral, femoral or
radius fracture. The exclusion criteria were a history of ven-
ous thromboembolic or malignant disease, serious renal im-
pairment, abnormal hepatic function, smoking, osteoporosis
therapy, lipid lowering or glucocorticoid treatment and
estrogen replacement therapy within previous 6 months.
Study protocol
Written informed consent was obtained from each individ-
ual and the study protocol was approved by the Slovenian
National Medical Ethics Committee. The patients were
treated for 12 months with 60 mg raloxifene per day and
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were followed in the University Medical Centre (Maribor,
Slovenia). Four patients were removed from the study due
to not following the study protocol.
At baseline, blood was drawn for measurements of
lipids, bone turnover markers and DNA extraction. All
investigations were carried out at 8 a.m. after an overnight
fast. After the first visit, the participants started with ralox-
ifene 60 mg, cholecalciferol 400 I.U. and calcium carbonate
1000 mg daily. Patients did not get any dietary advice.
Compliance was checked orally at the regular check-ups
by a physician three times during the study; after 3, 6 and
12 months of raloxifene therapy. After 12 months, blood
was drawn for measurement of bone turnover markers
(serum bone-specific alkaline phosphatase (BALP), serum
osteocalcin (OC), serum C-terminal telopeptide fragments
of type I collagen (CTX)), lipids and concentrations of
raloxifene, M1, M2 and M3. The blood was drawn at
8:00 a.m. visit to the hospital which corresponds to ap-
proximately 1–2 hours after the last dose. After centrifuga-
tion, the serum samples were stored at −86°C until
analysis. The BMD of total hip (BMD-HIP), femoral neck
(BMD-FN) and lumbar spine L1-L4 (BMD-LS,) and three
quantitative ultrasound parameters, heel speed of sound
(SOS), broadband ultrasound attenuation (BUA) and
quantitative ultrasound index (QUI) were measured at
baseline and after 12 months of raloxifene therapy.
Determination of raloxifene and its metabolites in serum
The method used for determination of M1, M2 and raloxi-
fene had been developed and validated previously in our la-
boratory and is described in full detail elsewhere [32].
Additionally, a new method for quantification of metabolite
M3 that was found in serum was developed and validated.
In the present study, the selected reaction monitoring
mode (SRM) set at 826! 474 (m/z transition) was used for
the quantification of M3 against the calibration curve for
raloxifene using a response factor obtained from incubating
the samples in a presence of beta-glucuronidase.
The linear range for M3 was from 0.88 nM to 4800
nM, the limit of quantification was 0.88 nM and the limit
of detection was 0.039 nM. The intra- and inter- day
coefficients of variation were 2.4 and 1.3%, respectively.
TR (total raloxifene) was calculated as a summation of
molar concentrations of raloxifene, M1, M2 and M3.
Determination of pharmacodynamic parameters
Bone mineral density (BMD) measurements
BMD-HIP, BMD-FN and BMD-LS were determined by
dual energy X-ray absorptiometry (DXA) with a Hologic
QDR-2000+ densitometer (Hologic Inc. Waltham, USA).
Quantitative ultrasound (QUS) measurements
QUS measurements of the calcaneus were performed on
the left heel of all study participants, with the subject in
the sitting position, using a Sahara apparatus (Hologic
Inc. Waltham, USA). Three QUS parameters of calca-
neus were measured: SOS, BUA and QUI. An average of
two measurements was calculated.
Bone turnover markers measurements
BALP was assessed by IRMA (TandemW-R OstaseW;
Beckman Coulter). OC was measured using a two-site
immunoluminometric Elecsys N-MID Osteocalcin assay
(Roche Diagnostics, Mannheim, Germany) [33]. CTX
was measured using a two-site immunoluminometric
Elecsys Beta CrossLaps assay (Roche Diagnostics, Mann-
heim Germany) [33].
Lipids analysis
Serum total cholesterol (HOL), HDL cholesterol, and tri-
glycerides (TG) were measured with enzymatic methods
(Olympus AU640 analyzer). LDL cholesterol was calcu-
lated by the Fridewald formula [34].
Monitoring of adverse effects
The patients reported the possible onset and the severity
of the most frequently described adverse effects asso-
ciated with raloxifene treatment, such as worsening of
hot flushes, leg cramps and swelling. No other adverse
effects were noted.
SLCO1B1 and SLCO1B3 genotyping
Genomic DNA was isolated from peripheral blood leuko-
cytes by using a FlexiGene DNA kit (Qiagen, Hilden,
Germany). Three SNPs in two different genes c.388A>G
(rs2306283) and c.521T>C (rs4149056) in the SLCO1B1
gene and C>G in intron 7 (rs17680137) of the SLCO1B3
gene were genotyped using validated TaqMan Assays
(C__1901697_20, C__30633906_10, C__25766725_10)
from Applied Biosystems in an ABI Prism 7000 se-
quence detection system, under the conditions recom-
mended by the manufacturer (Applied Biosystems,
Foster City, CA, USA). To validate our results, a random
selection of 10% of the samples was re-genotyped for
each SNP, and the results were found to be reproducible
with no discrepancies noted.
Statistical analysis
The Shapiro-Wilk goodness-of-fit test was used to
determine the normality of data distribution and the
Levene’s test was used to test the homogeneity of
variances prior to the ANOVA and the t-test. A
square root transformation was applied to the con-
centrations of raloxifene, M1, M2, M3 and TR in
order to obtain a normal data distribution. The
Bonferroni post hoc test was used to compare the
means from genotype groups for each polymorph-
ism. The calculation of the percentage change of
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the pharmacodynamic parameters (PD) during treat-
ment was calculated according to Eq.1.
ΔPDparameter ¼ PDparametert¼0−PDparametert¼12months
PDparameter0
 
 100%
ð1Þ
A Pearson’s correlation was used for the calculation of
associations between the serum concentrations of raloxi-
fene species and the percentage changes of pharmacody-
namic parameters. To test the influence of genotype on
raloxifene species concentration levels and on percentage
change of pharmacodynamic parameters during treatment,
the parametric t-test or ANOVA were applied. The Hardy-
Weinberg equilibrium was tested for each polymorph-
ism using the χ2 test. The significance criterion (α) was
set at p< 0.05. Data analyses were performed by PASW
18 software (IBM company, Illinois, Chicago). Program
PHASE version 2 was used for reconstructing haplo-
types from population data [35].
Results
Interaction of raloxifene and its three metabolites with
OATP1B1 and OATP1B3
The interaction potential of raloxifene and its metabolites
M1, M2 and M3 with the investigated transporters was
tested by observing the inhibition of OATP1B1 and
OATP1B3 mediated transport of E-3-S. The concentrations
of raloxifene, M1 and M2 used for the experiment were
10 μM, except for M3 that was 4 μM, because the available
amount of M3 was very low. Figure 1 shows that raloxifene
significantly inhibited OATP1B1 and that M2 and M3 sig-
nificantly inhibited OATP1B1 and OATP1B3 mediated
transport of E-3-S, respectively. Interestingly, M1 did not
interact with either OATP, while ICG as a positive control
for inhibition as expected completely abolished transport
activity of OATP1B1 and OATP1B3. In vitro findings
strongly indicate that OATP1B1 and OATP1B3 may be
involved in raloxifene disposition.
Patients' baseline characteristics and genotype frequencies
The baseline characteristics of 53 postmenopausal women
with osteoporosis enrolled in the study are presented in
Table 1.
Based on the in vitro results, the SNPs of SLCO1B1
c.388A>G, SLCO1B1 c.521T>C and SLCO1B3 int7C>G
[36] were analyzed. Genotype and haplotype frequencies are
presented in Table 2. In case of the SLCO1B1 c.521T>C
polymorphism there were no participants with the CC
genotype, so we compared only the TT and TC genotypes.
As there was only one participant with the GG genotype for
SLCO1B3 int7C>G polymorphism, we combined the
patients with GG and CG genotypes into the non-CC
group. The distribution of genotypes did not deviate signifi-
cantly from the Hardy-Weinberg equilibrium (p> 0.05).
Figure 1 Inhibitory effects of raloxifene species on active uptake of estrone-3-sulfate into CHO cells expressing OATP1B1 or OATP1B3.
Raloxifene-6-β-glucuronide (M1), raloxifene-4'- β -glucuronide (M2), raloxifene-6,4'-diglucuronide (M3), indocyanine green (ICG), estrone-3-sulfate
(E-3-S).E-3-S was used at concentration 0.5 μM, and cells were incubated with substrate and inhibitor for 5 minutes. The results are shown as
percentage of control uptake measured in the absence of inhibitor. Each column represents the mean± SD (n = 4) and (*) indicates a significant
difference from the control (p< 0.05).
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In case of haplotypes, only the influence of haplotypes
*1a, *1b and *15 was tested, but not *5, because there
were not enough patients with this haplotype.
Serum concentrations of raloxifene species in relation to
genotypes and haplotypes after 12 months of raloxifene
treatment
A high variability in serum concentrations of all measured
raloxifene species (M1, M2, M3, raloxifene, TR) was
observed between patients after 12 months of raloxifene
treatment. Mean serum concentrations (SD) were 70.1
(59.0), 315.6 (276.3), 510.0 (580.3), 3.6 (2.6) and 899.3
(829.7) for M1, M2, M3, raloxifene and TR, respectively
(Figure 2).
Statistical analyses showed a strong influence of
SLCO1B1 c.388A>G polymorphism on the concentra-
tions of raloxifene, M3 and TR. The levels of raloxifene,
M3 and TR were increasing from AA to GG individuals.
The same trend was observed for M1 and M2 concentra-
tions, but the differences were not statistically significant
(Table 3). SLCO1B1 c.388A>G polymorphism explains
26.3%, 22.8% and 20.8% of variability of M3, RAL, and
TR concentrations, respectively.
On the other hand, no statistically significant association
of serum raloxifene, M1, M2, M3 and TR concentrations
with SLCO1B1 c.521T>C and SLCO1B3 int7C>G poly-
morphisms was observed. However, a trend towards lower
concentrations of raloxifene and its metabolites in wild type
individuals compared to TC group (SLCO1B1 c.521T>C)
and to non-CC group (SLCO1B3 int7C>G) was observed,
but did not reach statistical significance (Table 3).
Additionally, the statistical analysis of raloxifene species
levels according to the number of copies of haplotypes for
SLCO1B1 showed that patients with more copies of *1b
haplotype have a higher concentration of M3, raloxifene
and TR. It was found out that *1b haplotype explains
32.3%, 18.6% and 17.7% of variability of M3, RAL, and TR
concentrations, respectively.
On the contrary, a contribution of *15 haplotype copies
to the concentrations of raloxifene species was not
observed. When testing the influence of the wild type
haplotype *1a on raloxifene species levels, significance was
observed for M3, raloxifene and TR. More copies of *1a
haplotype correspond to lower raloxifene species levels,
Table 1 Summary of baseline characteristics of 53
Caucasian postmenopausal women
mean (SD) Range
Age (year) 59.7 (6.2) 39.0 – 69.0
Years postmenopausal (year) 13.1 (6.9) 5.0 – 38.0
BMI (kg/m2) 25.6 (3.4) 18.9 – 34.9
SBP (mmHg) 143.4 (17.8) 105.0 – 190.0
DBP (mmHg) 85.5 (10.0) 60.0 – 105.0
BALP (μg/L) 12.2 (5.3) 4.9 – 29.1
OC (ng/mL) 33.5 (11.3) 10.0 – 60.3
CTX (ng/mL) 0.52 (0.19) 0.12 – 0.89
BUA (dB/MHz) 54.8 (11.5) 33.8 – 85.9
SOS (m/s) 1,513.5 (21.1) 1,464.4 – 1,562.6
QUI 72.0 (12.7) 43.9 – 104.9
BMD-HIP(g/cm2) 0.727 (0.096) 0.472 – 0.910
BMD-FN(g/cm2) 0.627 (0.076) 0.420 – 0.840
BMD-LS (g/cm2) 0.759 (0.071) 0.586 – 0.950
HOL (mmol/L) 5.85 (0.78) 4.31 – 7.37
HDL (mmol/L) 1.65 (0.31) 1.19 – 2.36
LDL (mmol/L) 3.53 (0.67) 2.17 – 4.81
TG (mmol/L) 1.50 (0.72) 0.67 – 4.03
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BALP, serum bone-specific alkaline phosphatase; OC, serum
osteocalcin; CTX, serum C-terminal telopeptide fragments of type I collagen;
BUA, broadband ultrasound attenuation; SOS, heel speed of sound; QUI,
quantitative ultrasound index; BMD-HIP, bone mineral density of total hip;
BMD-FN, bone mineral density of femoral neck; BMD-LS, bone mineral density
of lumbar spine.
Table 2 Genotype and haplotype frequencies of SLCO
polymorphisms in 53 postmenopausal patients with
osteoporosis
SLCO variant genotype number of
patients
frequency
(%)
SLCO1B1 c.388A>G AA 14 26.4
AG 28 52.8
GG 11 20.8
SLCO1B1 c.521T>C TT 35 66.0
TC 18 34.0
CC 0 0
SLCO1B3 int7C>G CC 36 67.9
CG 16 30.2
GG 1 1.9
SLCO1B1 haplotype number
haplotype copies
*1a
(reference
haplotype)
0 11 20.8
1 30 56.6
2 12 22.6
*1b (c.388A>G) 0 24 45.3
1 24 45.3
2 5 9.4
*5 (c.521T>C) 0 51 96.2
1 2 3.8
2 0 0
*15 (c.388A>G
and c.521T>C)
0 37 69.8
1 16 30.2
2 0 0
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which is consistent with the results for *1b haplotype
(Table 4).
Drug-drug pharmacokinetic interactions via OATPs
Drug-drug pharmacokinetic interactions via OATPs
have been evaluated on the basis of concomitant medi-
cation data of the patients. There were only few patients
receiving known substrates or inhibitors of OATP1B1
and/or OATP1B3 such as diclofenac [37], atorvastatin
[22] and enalapril [38]. Regarding the possibility of
drug-drug pharmacokinetic interactions via OATPs, the
results from the ANOVA test show that there were no
statistically significant influences of concomitantly
administered OATP substrates on raloxifene species
concentration levels. Vice-versa interactions cannot be
ruled out, however the concomitant medications con-
centration levels were not monitored, therefore no con-
clusions can be made.
Correlation of raloxifene species serum concentrations with
the percentage change of pharmacodynamic parameters
Pearson’s correlation analysis gave significant results for
correlation of M3 with Δ CTX (r =− 0.324, N= 40,
p = 0.044, two-tailed), TR with Δ CTX (r =− 0.376,
N= 40, p = 0.017, two-tailed) and M2 with the percentage
change of bone mineral density of lumbar spine (Δ
BMD-LS) (r = 0.320, N= 40, p = 0.044, two-tailed).
Impact of OATP1B1 and OATP1B3 genotypes and
haplotypes on the pharmacodynamic parameters
In all patients after 12 months of raloxifene therapy, all
the tested parameters (BALP, OC, CTX, BUA, SOS, QUI,
BMD-HIP, BMD-FN, BMD-LS, HOL, HDL, LDL, TG)
changed in the same way as previously observed [2-
4,6,8,9,11,39-42]. None of the three tested QUS para-
meters QUI, BUA and SOS showed any significant
changes after 12 months of therapy (data not shown).
Figure 2 Raloxifene concentrations according to the SLCO1B1 c.388A>G (rs2306283), SLCO1B1 c.521T>C, and SLCO1B3 int7C>G
polymorphisms.
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The relative changes of the selected pharmacodynamic
parameters after 12 months of raloxifene treatment were
evaluated according to SLCO1B1 c.388A>G, SLCO1B1
c.521T>C and SLCO1B3 int7C>G polymorphisms.
Table 5 shows a significant association of genotypes with
bone turnover markers BMD-FN, QUI and OC. It was
found out that tested polymorphisms explain up to 23%
of variability of the significantly changed Δ FN BMD, Δ
QUI and Δ OC.
Additionally, a statistical analysis of pharmacodynamic
parameters according to the SLCO1B1 haplotype was per-
formed and the significant results are presented in Table 5.
SLCO1B1 haplotypes explained up to 29% of the observed
variability of significant pharmacodynamic parameters.
Further, the influence of SLCO1B1 c.388A>G, SLCO1B1
c.521T>C and SLCO1B3 int7C>G polymorphisms on
HOL, HDL, LDL and TG was tested but no statistical sig-
nificance was observed (Table 6 and Table 7).
Discussion
The aim of our study was to investigate the role of up-
take transporters and their genetic variations in pharma-
cokinetics and pharmacodynamics of raloxifene in
postmenopausal osteoporosis.
Our in vitro experiments with OATP1B1 and OATP1B3
transfected CHO cell lines showed that M2 and M3 inter-
act with both, OATP1B1 and OATP1B3 transporters,
raloxifene interacts only with OATP1B1 and M1 does not
interact with any of the studied transporters. This does
not diminish the physiological importance of the tested
transporters, because as we have demonstrated, M1
in vivo concentrations are much lower compared to the
Table 3 Summary of concentrations of raloxifene species by SLCO1B1 and SLCO1B3 polymorphisms
Genotype
SLCO1B1 c.388A>G SLCO1B1 c.521T>C SLCO1B3 int7C>G
AA AG GG p value (ANOVA) TT TC p value (t-test) CC non-CC p value (t-test)
c (M1) (nmol/l) 60 (19) 63 (12) 99 (19) 0.143 65 (11) 79 (15) 0.400 68 (10) 75 (19) 0.830
c (M2) (nmol/l) 268 (90) 288 (53) 439 (101) 0.225 254 (43) 431 (85) 0.076 313 (51) 321 (77) 0.959
c (M3) (nmol/l) 266 (88) 395 (73) 1073 (305) 0.001a 545 (130) 446 (98) 0.917 411 (53) 715 (246) 0.339
c (RAL) (nmol/l) 1.9 (0.5) 3.5 (0.5) 5.6 (0.9) 0.004b 3.5 (0.6) 3.8 (0.5) 0.308 3.2 (0.4) 4.5 (0.8) 0.166
c (TR) (nmol/l) 596 (182) 750 (130) 1617 (381) 0.009c 867 (174) 960 (167) 0.519 795 (107) 1115 (321) 0.428
The values of concentrations are presented as means (standard errors).
aBonferoni post hoc test (ANOVA), p = 0.004 for AG vs. GG,p =0.001 for AA vs. GG.
bBonferoni post hoc test (ANOVA), p = 0.003 for AA vs. GG.
cBonferoni post hoc test (ANOVA), p = 0.014 for AA vs. GG,p =0.020 for AG vs. GG.
M1, raloxifene-6-β-glucuronide; M2, raloxifene-4'- β –glucuronide; M3, raloxifene-6,4'- di –glucuronide; RAL, raloxifene; TR, total raloxifene.
Table 4 Summary of concentrations of raloxifene species by haplotype
SLCO1B1 haplotype
*1b *15 *1a
No. of
haplotype
copies
0 1 2 p value
(ANOVA)
0 1 p value
(t-test)
0 1 2 p value
(ANOVA)
M1
(nmol/l)
61.8
(12.0)
72.9
(15.0)
92.6
(17.3)
0.437 66.0
(11.0)
78.4
(16.0)
0.497 99.4
(19.0)
64.3
(11.5)
55.9
(20.5)
0.125
M2
(nmol/l)
334.1
(72.0)
281.3
(57.1)
412.3
(122.9)
0.625 264.2
(42.5)
422.1
(90.8)
0.138 439.2
(101.7)
298.7
(52.3)
231.7
(93.0)
0.18
M3
(nmol/l)
305.8
(60.2)
482.7
(87.1)
1,572.3
(616.9)
0.0004a 533.1
(125.9)
462.3
(81.8)
0.954 1,072.7
(305.2)
388.1
(70.2)
273.3
(99.0)
0.001d
RAL
(nmol/l)
2.7
(0.5)
3.7
(0.5)
7.2
(1.8)
0.016b 3.5(0.5) 3.8
(0.5)
0.343 5.6 (0.9) 3.5
(0.5)
1.7
(0.6)
0.002e
TR
(nmol/I)
704.4
(137.6)
840.6
(154.0)
2,084.4
(751.6)
0.02c 866.8
(168.1)
966.9
(380.7)
0.549 1,616.9
(380.7)
754.6
(124.6)
592.6
(202.9)
0.007f
The values of concentrations are presented as means (standard errors).
aBonferoni test (ANOVA), p = 0.004 for 1 vs. 2 copies, p =0.0003 for 0 vs. 2 copies.
b Bonferoni test (ANOVA), p = 0.014 for 0 vs. 2 copies.
cBonferoni test (ANOVA), p = 0.017 for 0 vs 2 copies.
dBonferoni test (ANOVA), p = 0.004 for 0 vs. 1 copies, p =0.008 for 0 vs. 2 copies.
eBonferoni test (ANOVA), p = 0.003 for 0 vs. 2 copies.
fBonferoni test (ANOVA), p = 0.016 for 0 vs. 1 copies, p =0.019 for 0 vs. 2 copies.
M1, raloxifene-6-β-glucuronide; M2, raloxifene-4'- β –glucuronide; M3, raloxifene-6,4'- di –glucuronide; RAL, raloxifene; TR, total raloxifene.
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concentrations of M2 and M3. A direct transport of
raloxifene species into the transfected cell lines could
not be measured, because the radiolabelled raloxifene
species were not available. In addition, affinities or IC
50s could not be determined due to the very small
amount of available raloxifene metabolites.
On the basis of this in vitro data we decided to study the
effect of SLCO1B1 and SLCO1B3 genetic variants on the
pharmacokinetics and pharmacodynamics of raloxifene in a
group of Caucasian postmenopausal osteoporotic women.
Therefore, genotyping of three polymorphisms, SLCO1B1
c.388A>G, SLCO1B1 c.521T>C and SLCO1B3 int7C>
G which were previously shown to alter transporter activity
of some drugs [20-25] was performed. The SLCO1B1
c.388A>G polymorphism is responsible for the amino
acid substitution (p.N130D) in extracellular loop 2 of the
OATP1B1 protein and was shown to affect substrate speci-
ficity suggesting that this loop is involved in substrate
recognition [43,44]. This polymorphism could be respon-
sible for unchanged, increased or reduced transport activ-
ities of OATP1B1 [23,45-47]. On the other hand, it was
found that SLCO1B1 c.521T>C (p.V174A) polymorphism
decreases the membrane expression of OATP1B1 protein
and consequently lowers its transport activity [48]. Because
of the high allelic frequencies in Caucasian population, 41%
for c.388A>G and 18% for c.521T>C [49], and influence
on transport activities, the c.388A>G and c.521T>C poly-
morphisms could contribute to the high inter-individual
variability in pharmacokinetics and pharmacodynamics of
raloxifene. Additionally, a third polymorphism located in in-
tron 7 of SLCO1B3 gene was studied because of its strong
association with unconjugated bilirubin [36], whose levels
were found to correlate with those of raloxifene.
Serum concentrations of raloxifene, M1, M2 and M3
were determined using a validated method. To our know-
ledge, the developed LC/MS/MS method is the first
Table 6 Percentage change of lipids according to SLCO1B1 c.388A>G, SLCO1B1 c.521T>C and SLCO1B3 int7A>G
genotypes after 12 months of raloxifene treatment in 53 postmenopausal women
Genotype
SLCO1B1 c.388A>G SLCO1B1 c.521T>C SLCO1B3 int7 T!G
AA AG GG p value (ANOVA) TT TC p value (t-test) CC non CC p value (t-test)
Δ HOL (%) 0.08 (±2.41) −3.8 (±2.8) −6.9 (±2.0) 0.368 −4.0 (±1.9) −2.7 (±3.5) 0.725 −2.3 (±2.1) −6.1 (±2.7) 0.291
Δ HDL (%) −1.3 (±2.7) 3.0 (±3.2) −3.9 (±4.0) 0.379 0.7 (±2.5) 0.06 (±3.7) 0.890 1.7 (±2.4) −2.0 (±3.8) 0.393
Δ LDL (%) 2.7 (±3.8) −6.1 (±3.5) −10.3 (±3.4) 0.132 −4.9 (±2.5) −4.9 (±4.7) 0.994 −4.4 (±3.1) −5.8 (±3.2) 0.781
Δ TG (%) 12.9 (±12.8) −6.7 (±4.2) 21.3 (±12.1) 0.041a −1.2 (±6.8) 14.6 (±7.2) 0.124 6.8 (±6.4) −0.9 (±7.1) 0.455
The values are presented as means (standard errors).
aBonferoni test (ANOVA), no differences.
Table 5 Percentage change of pharmacodynamic parameters according to SLCO1B1 c.388A>G, SLCO1B1 c.521T>C
and SLCO1B3 int7A>G genotypes and SLCO1B1 haplotypes after 12 months of raloxifene treatment in 53
postmenopausal women
Pharmacodynamic parameter Δ FN BMD (%) Δ QUI (%) Δ OC (%)
genotype SLCO1B1 c.388A>G SLCO1B1 c.521T>C SLCO1B3 int7C>G
AA −1.1 (1.5) TT 2.5 (1.1) CC −21.0 (3.5)
AG 3.4 (0.6) TC −1.6 (1.4) non CC −33.5 (3.5)
GG −0.6 (1.1)
test/p-value ANOVA 0.001a t-test 0.033 t-test 0.015
Pharmacodynamic
parameter
Δ FN BMD (%) Δ CTX (%) Δ SOS (%) Δ QUI(%)
haplotype *1a *1b *15 *15
0 copies −0.65 (1.1) 0 copies −20.7 (6.7) 0 copies 0.2 (0.1) 0 copies 2.4 (1.1)
1 copy 3.5 (0.6) 1 copy −24.7 (5.1) 1 copy −0.3 (0.2) 1 copy −1.9 (1.6)
2 copies −2.0 (1.6) 2 copies −56.9 (10.4)
test/p-value ANOVA 0.0002b ANOVA 0.039c t-test 0.031 t-test 0.03
The values are presented as means (standard errors).
aBonferoni test (ANOVA), p = 0.004 for AA vs. AG, =0.021 for AG vs. GG.
bBonferoni test (ANOVA), p = 0.013 for 0 vs. 1, p = 0.0004 for 1 vs. 2 copies of haplotype*1a.
cBonferoni test (ANOVA), p = 0.035 for 0 vs. 2 copies of haplotype*1b.
Δ FN BMD (%), percentage change of femoral neck bone mineral density; Δ QUI (%), percentage change of quantitative ultrasound index; Δ OC (%), percentage
change of osteocalcin; Δ CTX (%), percentage change of serum C-terminal telopeptide fragments of type I collagen; Δ SOS (%), percentage change of heel speed of sound.
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method for detection of M1, M2, M3 and raloxifene. The
novelty of this contribution is the observation that the
main in vivo metabolite of raloxifene is M3. Our in vivo
study showed that the average raloxifene species serum
levels are in ratio of 1 : 19.5 : 87.7 : 141.7, for RAL, M1,
M2 and M3, respectively.
Serum levels of raloxifene, M3 and TR increase with the
number of SLCO1B1 c.388A>G mutated alleles. Levels of
M1 and M2 were visibly elevated as well, but due to the
small sample size and the pronounced data variability, a
statistical confirmation of this observation could not be
made. Analyses of possible combinations of both SLCO1B1
gene variants (haplotype) were consistent with the results
of individual testing of SLCO1B1 polymorphisms and
showed that haplotype *1b caused higher concentrations of
raloxifene, M3 and TR. These results could indicate that
the uptake of raloxifene in hepatocytes is lower and conse-
quently, the serum concentrations are higher. Moreover,
concentrations of metabolites also increase with the num-
ber of mutated alleles.
It is well known that only unconjugated raloxifene can
bind with high affinity to estrogen receptors to evoke a
pharmacodynamic response [18], although it represents
<1% of total serum raloxifene [15]. This small fraction of
unconjugated raloxifene found in systemic circulation ori-
ginates partly directly from the parent compound absorbed
from the gut and partly from the systemic cleavage of the
circulating glucuronides into raloxifene [17]. Hence, the
raloxifene metabolites actually represent transport forms
and a depot of active raloxifene. Given the extremely low
and highly variable raloxifene concentrations, the serum
levels of raloxifene metabolites can be used as a measure
of raloxifene exposure.
Our correlation analysis between serum levels of raloxi-
fene species with clinical parameters showed higher levels
of M3 and TR in patients with a higher decrease in serum
CTX, one of the most reliable bone resorption markers
[50], thus implicating a better antiresorptive effect of
raloxifene in those patients. In addition, higher M2 con-
centrations were found to correlate with a greater increase
in BMD at lumbar spine (BMD-LS) but not with BMD
values at other sites of skeleton. This is in concordance
with the already known “site specific” bone effects during
raloxifene treatment, which is therefore predominantly
used for the prevention of vertebral osteoporotic fractures
and not for hip or wrist or any other common osteoporotic
fractures. Based on this correlation, the influence of
SLCO1B1 and SLCO1B3 genetic variants on clinical out-
comes was tested: a lowering of bone turnover markers, an
increase of bone quality (QUI measurements) and an in-
crease in bone mineral density. The CTX was shown to be
influenced by a number of *1b haplotype copies, which
was shown also to increase the raloxifene species plasma
concentration, that most probably caused a higher de-
crease in CTX during treatment. A statistical significance
was observed also in change of BMD-FN regarding
SLCO1B1 c.388A>G polymorphism and *1a haplotype
but due to the small sample size, only modest changes in
BMD-FN in one year and the inherent measurement error
by DXA [51] the direction could not be determined. Add-
itionally, no influence of SLCO1B1 and SLCO1B3 genetic
variants on HOL, HDL, LDL and TG was observed.
Beside the influence of SLCO1B1 and SLCO1B3 genetic
variants on raloxifene pharmacokinetics and pharmaco-
dynamics the influence of studied polymorphisms on the
probability of raloxifene adverse effects was also evaluated.
The statistical analysis did not establish any correlation of
studied polymorphisms with the probability of raloxifene
adverse effects because the study was not designed for this
purpose and number of patients was too low. Further stud-
ies with higher number of patients are needed to discover
the possible associations of genetic polymorphisms with
raloxifene adverse effects.
Our results indicate that a significant part (up to 20%) of
the observed high inter-individual variability in pharmaco-
kinetics and pharmacodynamics can be explained by a
genetic influence of the SLCO1B1 c.388A>G polymorph-
ism. Therefore, pharmacogenetics of SLCO1B1 could be
taken into account to individualize raloxifene therapy.
The main limitation of the current in vivo study is a ra-
ther small number of the enrolled participants. Additionally,
the duration of our study should be prolonged due to very
minimal changes in BMD observed in one year. Other phar-
macodynamic parameters and concentrations of raloxifene
Table 7 Percentage change of lipids according to SLCO1B1 haplotypes after 12 months of raloxifene treatment in 53
postmenopausal women
Haplotype
*1b *15 *1a
Number of copies
of haplotype
0 1 2 p value
(ANOVA)
0 1 p value
(t-test)
0 1 2 p value
(ANOVA)
Δ HOL (%) −0.8 (2.9) −4.8 (2.2) −10.2 (3.0) 0.228 −3.9 (1.8) −2.8 (3.7) 0.747 −6.9 (2.0) −3.8 (2.7) 0.3 (2.6) 0.363
Δ HDL (%) −0.7 (2.9) 3.8 (3.2) −9.7 (5.3) 0.149 0.5 (2.4) 0.3 (4.0) 0.963 −3.9 (4.0) 2.7 (3.1) −1.0 (3.0) 0.416
Δ LDL (%) −0.05 (4.01) −7.8 (2.7) −13.0 (5.8) 0.140 −4.8 (2.5) −5.2 (5.0) 0.935 −10.3 (3.4) −5.9 (3.4) 3.0 (4.1) 0.140
Δ TG (%) 8.7 (7.7) −1.0 (6.4) 7.8 (20.7) 0.626 −0.7 (6.0) 14.5 (7.7) 0.145 21.3 (12.1) −5.9 (4.2) 12.7 (14.0) 0.051
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species should also be monitored in such prolonged study.
Moreover, multiple comparisons may be the cause for the
reported positive associations. As such, our results are ex-
ploratory in nature and should be interpreted as hypothesis
generating and confirmed by the accomplishment of a lager
study. However, it is our opinion that the present in vivo
study in connection with the in vitro data allows to make
stated interpretations.
Conclusions
In conclusion, this is the first study where in vitro research
of uptake transporters for raloxifene and its metabolites
was performed and also the first study to assess the influ-
ence of SLCO1B1 and SLCO1B3 polymorphisms on
pharmacokinetics and pharmacodynamics of raloxifene. It
was shown that raloxifene interacts with OATP1B1 and
M2 and M3 interact with both tested uptake transporters.
Furthermore, despite the small number of study partici-
pants, the in vivo evidence showed the influence of
SLCO1B1 388A>G polymorphism and *1b haplotype on
pharmacokinetics and pharmacodynamics of raloxifene.
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